Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 (Oral Stable Form) | Pentadeca Arginate (PDA) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection. |
| Timing | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. | Administer on an empty stomach. Inject near site of injury for localized effect. |
| Cycle Duration | 4-12 weeks. Oral form enables easier long-term use compared to injectable. | 4-12 weeks depending on therapeutic target. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
Administer on an empty stomach. Inject near site of injury for localized effect.
4-12 weeks depending on therapeutic target.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →